Woodstock Corp grew its stake in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) by 1.3% through the 4th quarter, in response to the corporate in its most up-to-date 13F submitting with the SEC. The institutional investor owned 129,205 shares of the corporate’s inventory after shopping for a further 1,700 shares through the quarter. Merck & Co., Inc. accounts for 1.9% of Woodstock Corp’s funding portfolio, making the inventory its thirteenth largest place. Woodstock Corp’s holdings in Merck & Co., Inc. have been value $14,335,000 as of its most up-to-date submitting with the SEC.
Different institutional traders and hedge funds have additionally not too long ago made adjustments to their positions within the firm. Legend Monetary Advisors Inc. bought a brand new place in Merck & Co., Inc. within the third quarter value $27,000. EdgeRock Capital LLC bought a brand new place in Merck & Co., Inc. within the third quarter value $30,000. Mach 1 Monetary Group LLC bought a brand new place in Merck & Co., Inc. within the third quarter value $30,000. New Millennium Group LLC bought a brand new place in Merck & Co., Inc. within the 2nd quarter value $35,000. Lastly, Horizons Wealth Administration bought a brand new place in Merck & Co., Inc. within the 2nd quarter value $42,000. Hedge funds and different institutional traders personal 72.89% of the corporate’s inventory.
Merck & Co., Inc. Buying and selling Down 3.0 %
NYSE:MRK opened at $104.10 on Friday. Merck & Co., Inc. has a one 12 months low of $78.63 and a one 12 months excessive of $115.49. The corporate has a debt-to-equity ratio of 0.62, a present ratio of 1.47 and a fast ratio of 1.23. The corporate’s 50-day easy transferring common is $108.19 and its 200 day easy transferring common is $102.15. The agency has a market capitalization of $264.27 billion, a P/E ratio of 18.23, a PEG ratio of 1.95 and a beta of 0.34.
Merck & Co., Inc. (NYSE:MRK – Get Rating) final issued its earnings outcomes on Thursday, February 2nd. The corporate reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.56 by $0.06. The agency had income of $13.83 billion for the quarter, in comparison with the consensus estimate of $13.66 billion. Merck & Co., Inc. had a web margin of 24.49% and a return on fairness of 43.47%. The enterprise’s income was up 2.3% on a year-over-year foundation. Throughout the identical quarter within the prior 12 months, the agency posted $1.80 earnings per share. As a bunch, analysts forecast that Merck & Co., Inc. will submit 6.88 EPS for the present fiscal 12 months.
Merck & Co., Inc. Dividend Announcement
The corporate additionally not too long ago introduced a quarterly dividend, which can be paid on Monday, April tenth. Stockholders of file on Wednesday, March fifteenth can be paid a $0.73 dividend. The ex-dividend date is Tuesday, March 14th. This represents a $2.92 annualized dividend and a dividend yield of two.80%. Merck & Co., Inc.’s dividend payout ratio is presently 51.14%.
Insider Transactions at Merck & Co., Inc.
In different information, EVP Steven Mizell bought 4,436 shares of the corporate’s inventory in a transaction that occurred on Monday, February sixth. The shares have been bought at a mean worth of $104.25, for a complete worth of $462,453.00. Following the transaction, the chief vice chairman now owns 39,900 shares within the firm, valued at $4,159,575. The sale was disclosed in a authorized submitting with the SEC, which is accessible at this link. In different information, EVP Steven Mizell bought 4,436 shares of the enterprise’s inventory in a transaction that occurred on Monday, February sixth. The shares have been bought at a mean worth of $104.25, for a complete transaction of $462,453.00. Following the completion of the transaction, the chief vice chairman now immediately owns 39,900 shares of the corporate’s inventory, valued at $4,159,575. The transaction was disclosed in a submitting with the Securities & Trade Fee, which might be accessed via the SEC website. Additionally, insider Joseph Romanelli bought 5,000 shares of the enterprise’s inventory in a transaction that occurred on Wednesday, February fifteenth. The shares have been bought at a mean worth of $108.22, for a complete transaction of $541,100.00. Following the transaction, the insider now immediately owns 20,284 shares of the corporate’s inventory, valued at $2,195,134.48. The disclosure for this sale might be discovered here. During the last 90 days, insiders have bought 100,245 shares of firm inventory value $11,168,256. Company insiders personal 0.29% of the corporate’s inventory.
Analyst Upgrades and Downgrades
Plenty of equities analysts have issued studies on the inventory. Wells Fargo & Firm minimize shares of Merck & Co., Inc. from an “obese” score to an “equal weight” score and decreased their worth goal for the corporate from $120.00 to $115.00 in a analysis report on Monday, March thirteenth. Barclays boosted their worth goal on shares of Merck & Co., Inc. from $110.00 to $128.00 in a analysis report on Tuesday, December twentieth. Mizuho restated a “purchase” score and issued a $130.00 worth goal on shares of Merck & Co., Inc. in a analysis report on Friday. Financial institution of America upgraded shares of Merck & Co., Inc. from a “impartial” score to a “purchase” score and boosted their worth goal for the corporate from $110.00 to $130.00 in a analysis report on Wednesday, January 4th. Lastly, Cantor Fitzgerald boosted their worth goal on shares of Merck & Co., Inc. from $120.00 to $135.00 and gave the corporate an “obese” score in a analysis report on Monday, December nineteenth. 5 equities analysis analysts have rated the inventory with a maintain score and sixteen have assigned a purchase score to the inventory. Primarily based on knowledge from MarketBeat, the inventory has a consensus score of “Reasonable Purchase” and a consensus goal worth of $119.35.
Merck & Co., Inc. Firm Profile
Merck & Co, Inc is a well being care firm, which engages within the provision of well being options via its prescription medicines, vaccines, biologic therapies, animal well being, and client care merchandise. It operates via the next segments: Pharmaceutical, Animal Well being, and Different. The Pharmaceutical phase contains human well being pharmaceutical and vaccine merchandise.
Learn Extra
Wish to see what different hedge funds are holding MRK? Visit HoldingsChannel.com to get the most recent 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Get Rating).
Obtain Information & Scores for Merck & Co. Inc. Day by day – Enter your e-mail tackle under to obtain a concise every day abstract of the most recent information and analysts’ rankings for Merck & Co. Inc. and associated corporations with MarketBeat.com’s FREE every day e-mail e-newsletter.
